bioAffinity Technologies adds talent in march to market

PUBLISHED ON December 11, 2017

San Antonio Business Journal (December 8, 2017) In an effort to shore up plans to commercialize its initial product, bioAffinity Technologies is adding more scientific and financial firepower to its arsenal. The San Antonio-based biotech is expanding its leadership team.

read more

bioAffinity Technologies Welcomes New Board Members

PUBLISHED ON November 30, 2017

SAN ANTONIO, TX (Nov. 29, 2017) bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors.

read more

bioAffinity Selected as One of Texas’s Healthcare Innovators

PUBLISHED ON November 5, 2017

San Antonio Business Journal (October 31, 2017) bioAffinity Technologies is proud to be chosen by the Texas Business Journals as one of the state's Healthcare Innovators. The recognition for our research that is leading to groundbreaking early cancer diagnostic tests by our dedicated team of scientists is truly appreciated.

read more

San Antonio Company Develops A New Test For Lung Cancer

PUBLISHED ON August 24, 2017

Texas Public Radio (August 24, 2017 ) A new, more accurate, test for lung cancer is being developed in San Antonio. It’s a screening that could help save the lives of thousands of people who are often diagnosed too late to survive the disease.

read more

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.